Therapeutics News and Research

RSS

COVID-19 immunity shows cross-reactivity against related bat coronaviruses

People who recovered from COVID-19 infection or were vaccinated against SARS-CoV-2 are more likely to have immunity to other closely related bat coronaviruses that could have the potential to threaten future human health.

1 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

Mitochondrial protein SLC25A34 links body clock, cold and diet to brown fat metabolism

Brown fat burns fuel to make heat, and this activity is controlled by the body clock: dropping during sleep and rising before waking. But a cold morning or a skipped meal makes demands the clock never planned for.

1 Oct 2026

New project explores mitochondrial evolution across diverse life forms

A research consortium has generated the broadest look yet at the proteins that make up mitochondria, capturing the organelle's diversity across multiple branches on the tree of complex life.

1 Oct 2026

Varying mutation rates in healthy organs explain cancer risk

A new study by scientists at City of Hope® and TGen, part of City of Hope, found surprisingly large differences in the number of mutations present in organs of healthy individuals.

1 Oct 2026

Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.

1 Oct 2026

Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV

Highlight Therapeutics, a clinical‑stage biotechnology company developing immune activators to transform the treatment of skin tumors, today announced positive results from the multicenter, single-arm Phase 2b SPOTLIGHT‑204 clinical trial evaluating BO‑112, a novel dsRNA-based intralesional treatment for patients with resectable primary low‑ and high‑risk basal cell carcinoma (BCC).

1 Oct 2026

Wearable AI forecasts prolonged sitting in women with chronic pelvic pain disorders

Researchers at the Icahn School of Medicine at Mount Sinai have developed an artificial intelligence (AI) approach using data from wearable devices that can forecast upcoming periods of prolonged sitting in women with chronic pelvic pain disorders.

30 Sep 2026

Novo Nordisk Foundation funds genomic research into metabolic diseases

The Novo Nordisk Foundation has committed $53 million to renew and expand the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease at the Broad Institute, led by managing director Kasper Lage.

30 Sep 2026

New mathematical model tracks how tumor environment impacts cancer therapies

Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).

30 Sep 2026

Fractionated radiation reduces brain cancer recurrence and boosts survival

Mayo Clinic researchers led a multicenter study that found dividing radiation into several treatments, known as fractionated stereotactic radiosurgery, reduced the risk of cancer returning after surgery for brain metastases and was associated with improved survival compared with delivering radiation in a single treatment.

30 Sep 2026

Laverock Therapeutics announces in vivo programs in oncology and genetic medicine

Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announces its in vivo programs spanning CAR-T and genetic medicine

From Laverock Therapeutics 30 Sep 2026

Study identifies three cell clusters driving pancreatic cancer-induced cachexia

Research published today in Cell identifies three small subclusters of cells driving pancreatic cancer-induced cachexia, a muscle-wasting and fat-loss condition that makes patients less tolerant of cancer treatment.

29 Sep 2026

Targeting specific nuclear receptor could help preserve aging muscle function

Scientists in the Gerhart-Hines Group pinpoint a molecular cause of muscle aging, and a possible fix. By investigating how muscles adapt to age and disease-related decline, the scientists discovered the involvement of a druggable nuclear receptor, ERRγ, that could be targeted to preserve muscle function.

29 Sep 2026

Blood tests can identify cancer neoantigens for personalized immunotherapy

Cancer neoantigens and neoantigen-specific T cells were identified from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells, respectively, and they largely matched those found through traditional tumor tissue biopsy in many patients.

29 Sep 2026

An approved Ebola antibody may miss its mark against Bundibugyo virus

Researchers analyzed 44 Bundibugyo virus genomes and modeled how approved and experimental Ebola antibodies might bind the virus’s glycoprotein. The models predicted disrupted binding for Ebanga, conserved targets for MBP134, and different binding behavior for the complete Inmazeb cocktail than for two of its antibodies alone; laboratory tests are needed to determine whether these findings translate into treatment benefit.

28 Sep 2026

MIT engineers use artificial intelligence to create heat-resistant RNA vaccines

MIT engineers have found a way to stabilize the lipid nanoparticles used to deliver RNA vaccines, which could allow the vaccines to be more widely distributed.

28 Sep 2026

New study tracks rising heart and kidney risks in people with type 2 diabetes

The risk of developing chronic kidney disease (CKD) or heart failure (HF), or dying, following a type 2 diabetes (T2D) diagnosis increases substantially over time, according to new research being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

27 Sep 2026

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd)-negative brain lesions.

26 Sep 2026

UCLA researchers present new radiation advances at ASTRO 2026

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share new research and clinical trial findings at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on new treatment approaches for prostate, bile duct and head and neck cancers, personalized radiation therapy based on genetic risk, and advances in targeted radiation and radioligand therapy designed to improve cancer control while limiting treatment side effects.

25 Sep 2026